EC
PROK icon

EntryPoint Capital’s ProKidney PROK Stock Holding History

EntryPoint Capital’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-82,862
Closed -$148K – 931
2026
Q1 		$148K Buy
82,862
+54,045
+188% +$115K 0.04% 677
2025
Q4 		$64.5K Buy
+28,817
New +$75.8K 0.03% 626
2024
Q4 		– Sell
-16,998
Closed -$32.6K – 918
2024
Q3 		$32.6K Buy
+16,998
New +$38.6K 0.02% 592

Other funds holding PROK

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $542M AUM 206.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

EntryPoint Capital's PROK Position: Q2 2026 in Review

EntryPoint Capital sold out of ProKidney (PROK) in Q2 2026, closing a stake of 82,862 shares — an estimated $148K sold.

EntryPoint Capital first reported a position in PROK in Q3 2024 and held it in 3 quarters. The position peaked at $148K in Q1 2026. 71 funds tracked by Wall St. Rank hold PROK as of Q2 2026.

  • EntryPoint Capital reported no remaining ProKidney position as of Q2 2026 after selling out during the quarter.
  • EntryPoint Capital sold 82,862 ProKidney shares in Q2 2026, an estimated $148K.
  • EntryPoint Capital first reported a position in ProKidney in Q3 2024 and held it in 3 quarters.
  • EntryPoint Capital's ProKidney position peaked at $148K in Q1 2026.
  • 71 funds tracked by Wall St. Rank held ProKidney as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.